Maybe because 177Lu-PSMA-617 is fantastic treatment getting fantastic results.
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks.
Rasul S, et al. Eur J Nucl Med Mol Imaging. 2020
The majority of patients were previously treated with abiraterone/enzalutamide (69%) and docetaxel/cabazitaxel (67%). In total, 79% of the patients showed a decrease in PSA (median PSA decrease from 66 to 19.8, range 0.7-4563 μg/L, P < 0.001) 1 month after the 3rd therapy cycle. Among them, 58% and 35% demonstrated a PSA-decline of > 50% and > 80%, respectively. Median OS was 119 weeks; median PFS was 25 weeks.
https://www.ncbi.nlm.nih.gov/m/pubmed/31781834/
Ann: Pronounced survival benefit in LuPIN interim trial data, page-9
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.91M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 12000 | 1 |
View Market Depth
| Last trade - 16.12pm 17/07/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable